290 related articles for article (PubMed ID: 23991039)
21. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
Wibmer CK; Gorman J; Ozorowski G; Bhiman JN; Sheward DJ; Elliott DH; Rouelle J; Smira A; Joyce MG; Ndabambi N; Druz A; Asokan M; Burton DR; Connors M; Abdool Karim SS; Mascola JR; Robinson JE; Ward AB; Williamson C; Kwong PD; Morris L; Moore PL
PLoS Pathog; 2017 Jan; 13(1):e1006074. PubMed ID: 28076415
[TBL] [Abstract][Full Text] [Related]
22. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.
Ditzel HJ; Binley JM; Moore JP; Sodroski J; Sullivan N; Sawyer LS; Hendry RM; Yang WP; Barbas CF; Burton DR
J Immunol; 1995 Jan; 154(2):893-906. PubMed ID: 7529290
[TBL] [Abstract][Full Text] [Related]
23. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
[TBL] [Abstract][Full Text] [Related]
25. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
Wu X; Yang ZY; Li Y; Hogerkorp CM; Schief WR; Seaman MS; Zhou T; Schmidt SD; Wu L; Xu L; Longo NS; McKee K; O'Dell S; Louder MK; Wycuff DL; Feng Y; Nason M; Doria-Rose N; Connors M; Kwong PD; Roederer M; Wyatt RT; Nabel GJ; Mascola JR
Science; 2010 Aug; 329(5993):856-61. PubMed ID: 20616233
[TBL] [Abstract][Full Text] [Related]
26. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
Wu L; Zhou T; Yang ZY; Svehla K; O'Dell S; Louder MK; Xu L; Mascola JR; Burton DR; Hoxie JA; Doms RW; Kwong PD; Nabel GJ
J Virol; 2009 May; 83(10):5077-86. PubMed ID: 19264769
[TBL] [Abstract][Full Text] [Related]
27. Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.
Dubrovskaya V; Guenaga J; de Val N; Wilson R; Feng Y; Movsesyan A; Karlsson Hedestam GB; Ward AB; Wyatt RT
PLoS Pathog; 2017 Sep; 13(9):e1006614. PubMed ID: 28902916
[TBL] [Abstract][Full Text] [Related]
28. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
Utachee P; Nakamura S; Isarangkura-Na-Ayuthaya P; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
J Virol; 2010 May; 84(9):4311-20. PubMed ID: 20164234
[TBL] [Abstract][Full Text] [Related]
29. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.
Crooks ET; Tong T; Chakrabarti B; Narayan K; Georgiev IS; Menis S; Huang X; Kulp D; Osawa K; Muranaka J; Stewart-Jones G; Destefano J; O'Dell S; LaBranche C; Robinson JE; Montefiori DC; McKee K; Du SX; Doria-Rose N; Kwong PD; Mascola JR; Zhu P; Schief WR; Wyatt RT; Whalen RG; Binley JM
PLoS Pathog; 2015 May; 11(5):e1004932. PubMed ID: 26023780
[TBL] [Abstract][Full Text] [Related]
30. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.
Fouts TR; Binley JM; Trkola A; Robinson JE; Moore JP
J Virol; 1997 Apr; 71(4):2779-85. PubMed ID: 9060632
[TBL] [Abstract][Full Text] [Related]
31. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.
Chen L; Kwon YD; Zhou T; Wu X; O'Dell S; Cavacini L; Hessell AJ; Pancera M; Tang M; Xu L; Yang ZY; Zhang MY; Arthos J; Burton DR; Dimitrov DS; Nabel GJ; Posner MR; Sodroski J; Wyatt R; Mascola JR; Kwong PD
Science; 2009 Nov; 326(5956):1123-7. PubMed ID: 19965434
[TBL] [Abstract][Full Text] [Related]
32. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
[TBL] [Abstract][Full Text] [Related]
33. Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.
Powell RLR; Totrov M; Itri V; Liu X; Fox A; Zolla-Pazner S
J Virol; 2017 Sep; 91(17):. PubMed ID: 28615206
[TBL] [Abstract][Full Text] [Related]
34. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.
Chakrabarti BK; Walker LM; Guenaga JF; Ghobbeh A; Poignard P; Burton DR; Wyatt RT
J Virol; 2011 Aug; 85(16):8217-26. PubMed ID: 21653673
[TBL] [Abstract][Full Text] [Related]
35. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
[TBL] [Abstract][Full Text] [Related]
36. Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement.
Liu Q; Zhang P; Miao H; Lin Y; Kwon YD; Kwong PD; Rikhtegaran-Tehrani Z; Seaman MS; DeVico AL; Sajadi MM; Lusso P
J Virol; 2021 May; 95(12):. PubMed ID: 33827946
[TBL] [Abstract][Full Text] [Related]
37. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.
Guan Y; Pazgier M; Sajadi MM; Kamin-Lewis R; Al-Darmarki S; Flinko R; Lovo E; Wu X; Robinson JE; Seaman MS; Fouts TR; Gallo RC; DeVico AL; Lewis GK
Proc Natl Acad Sci U S A; 2013 Jan; 110(1):E69-78. PubMed ID: 23237851
[TBL] [Abstract][Full Text] [Related]
38. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
39. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
Liang Y; Guttman M; Williams JA; Verkerke H; Alvarado D; Hu SL; Lee KK
J Virol; 2016 Oct; 90(20):9224-36. PubMed ID: 27489265
[TBL] [Abstract][Full Text] [Related]
40. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
